Literature DB >> 22460811

Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development.

Peggy S Sullivan1, Erin L Maresh, David B Seligson, Omar Habeeb, Madhuri Wadehra, Lee Goodglick, Oliver Dorigo.   

Abstract

Thyroid transcription factor-1 (TTF-1) is a DNA-binding protein that is mainly expressed in thyroid and lung tissue, but has also been found in gynecologic tissue. Recent studies have suggested that TTF-1 has tumor suppressor function in lung adenocarcinoma models. In the current study, we examined whether expression of TTF-1 in benign endometrium and endometrial hyperplasia might impact on the risk of developing endometrial cancer. Formalin-fixed paraffin-embedded endometrial tissues obtained from 535 cases were used to construct an endometrial tissue microarray. One hundred fifty of 207 patients had multiple serial endometrial specimens including 46 patients who progressed to endometrial cancer. The tissue microarray included a range of histopathologies including benign endometrium (n=231), simple hyperplasia (n=105), complex hyperplasia (n=36), simple atypical hyperplasia (n=10), complex atypical hyperplasia (n=44), and endometrial carcinoma (n=109). Expression of TTF-1 by immunohistochemistry in benign endometrium and endometrial hyperplasia was correlated with progression to cancer and clinical features known to be associated with increased risk of developing endometrial cancer. Carcinoma specimens showed a significantly greater expression of TTF-1 compared with benign endometrium and non-atypical hyperplasia (P=0.0007 and P=0.05). Presence of TTF-1 expression in benign endometrium was associated with a significantly decreased risk of cancer development (P=0.003, hazards ratio=0.104, 95% CI: 0.024-0.455). TTF-1 expression in hyperplasia did not significantly correlate with progression to cancer. The data from our study show that TTF-1 expression in normal endometrium is associated with a reduced risk of endometrial cancer development. This observation suggests that TTF-1 might function as a tumor suppressor in endometrial tissue. TTF-1 expression in normal endometrium could potentially provide clinically useful information as a biomarker for the risk of endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460811      PMCID: PMC3845815          DOI: 10.1038/modpathol.2012.64

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  33 in total

1.  Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

Authors:  Richard J Zaino; James Kauderer; Cornelia Liu Trimble; Steven G Silverberg; John P Curtin; Peter C Lim; Donald G Gallup
Journal:  Cancer       Date:  2006-02-15       Impact factor: 6.860

Review 2.  The antiestrogenic effect of cigarette smoking in women.

Authors:  J A Baron; C La Vecchia; F Levi
Journal:  Am J Obstet Gynecol       Date:  1990-02       Impact factor: 8.661

3.  Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites.

Authors:  O Kaufmann; M Dietel
Journal:  Histopathology       Date:  2000-05       Impact factor: 5.087

4.  Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

Authors:  Rebecca Siegel; Elizabeth Ward; Otis Brawley; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-06-17       Impact factor: 508.702

5.  Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.

Authors:  G L Mutter; M C Lin; J T Fitzgerald; J B Kum; J P Baak; J A Lees; L P Weng; C Eng
Journal:  J Natl Cancer Inst       Date:  2000-06-07       Impact factor: 13.506

6.  Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas.

Authors:  P A Bejarano; R P Baughman; P W Biddinger; M A Miller; C Fenoglio-Preiser; B al-Kafaji; R Di Lauro; J A Whitsett
Journal:  Mod Pathol       Date:  1996-04       Impact factor: 7.842

Review 7.  Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas.

Authors:  N G Ordóñez
Journal:  Adv Anat Pathol       Date:  2000-03       Impact factor: 3.875

8.  Hormone replacement therapy is associated with decreased survival in women with lung cancer.

Authors:  Apar Kishor Ganti; Abe E Sahmoun; Amit W Panwalkar; Ketki K Tendulkar; Anil Potti
Journal:  J Clin Oncol       Date:  2005-11-28       Impact factor: 44.544

9.  Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray.

Authors:  A Alkushi; J Irving; F Hsu; B Dupuis; C L Liu; M Rijn; C B Gilks
Journal:  Virchows Arch       Date:  2003-02-12       Impact factor: 4.064

10.  The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin.

Authors:  J L Hecht; J L Pinkus; L J Weinstein; G S Pinkus
Journal:  Am J Clin Pathol       Date:  2001-10       Impact factor: 2.493

View more
  1 in total

1.  A large cohort study of hypothyroidism and hyperthyroidism in relation to gynecologic cancers.

Authors:  Jae H Kang; Angela S Kueck; Richard Stevens; Gary Curhan; Immaculata De Vivo; Bernard Rosner; Erik Alexander; Shelley S Tworoger
Journal:  Obstet Gynecol Int       Date:  2013-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.